Novartis is one of the world’s leading medicines companies. We use innovative science and technology to address some of society’s most challenging healthcare issues. Worldwide, our medicines reached 743 million people in 2022.
Our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Our vision is to become the most valued and trusted medicines company in the world.
We have two operating divisions: Innovative Medicines, which specializes in patent-protected medicines, and Sandoz, which sells high-quality generics and biosimilars. Innovative Medicines is the larger of our two divisions in terms of consolidated net sales. These divisions are supported by our research and development (R&D) teams, our Operations organization and our corporate functions.
Click to explore
Operations and corporate functions
Operations manufactures and delivers medicines to customers and takes care of IT and other support services across the organization. In 2022, our manufacturing facilities shipped approximately 72.5 billion treatments.
Corporate functions provide expertise in areas such as finance, human resources, legal, and communications, as well as ethics, risk and compliance. Our Strategy and Growth function combines corporate strategy, R&D portfolio strategy and business development.
We reached approximately 54 million patients in 2022 through our Global Health function, which focuses on transforming health in low- and middle-income countries.
The Sandoz Division is a global leader in high-quality, affordable generics and biosimilars. Sandoz reached approximately 453 million patients in 2022.
Innovative Medicines comprises two commercial units: Innovative Medicines US and Innovative Medicines International. These units were created in April 2022 as part of our new, integrated organizational structure. Our Innovative Medicines Division reached approximately 236 million patients in 2022.
Research and development
At the heart of our company is research and development (R&D). Novartis consistently ranks among the world’s top companies investing in R&D:
- The Novartis Institutes for BioMedical Research (NIBR) is our innovation engine, focused on discovering new medicines for diseases with unmet medical need. Our Global Drug Development (GDD) organization oversees the development of potential new medicines, running large clinical trials and steering the way to regulatory approval for general use in patients.